Flurries Of New Bills Advance Device Industry Interests In Congress
This article was originally published in The Gray Sheet
The first legislative salvos were launched last week in a battle that is sure to escalate in conjunction with device user fee reauthorization efforts next year.
You may also be interested in...
Burgess Still Wants to Limit FDA LDT Oversight
Despite failing to move on a bill to restrict FDA oversight of lab developed tests (LDT) or reintroducing the bill in recent sessions, Rep. Michael Burgess, R-Texas, says he still supports the idea and is still working on trying to limit the agency's authority.
Lab Groups’ LDT Comments Will Highlight Barriers To Test Accessibility
Laboratory groups, who are facing the prospect of a new regulatory scheme in FDA’s proposed lab-developed test framework, intend to discuss barriers to test accessibility and clinical validation of LDTs.